Hormel Foods Corp. reported preliminary first‑quarter fiscal 2026 results on February 17, 2026, with net sales of approximately $3.00 billion, a 2% organic growth rate, diluted earnings per share of $0.33 and adjusted diluted EPS of $0.34. The adjusted EPS beat the consensus estimate of $0.32 by $0.02, while revenue fell short of the $3.06 billion consensus by $60 million.
The company’s revenue performance reflected a mix shift toward higher‑margin branded products. Core retail and foodservice segments grew modestly, offset by a decline in the legacy whole‑bird turkey business, which is being sold to Life‑Science Innovations. The divestiture is expected to close by the end of fiscal Q2 2026 and is projected to have a minimal impact on the company’s full‑year guidance.
Hormel reaffirmed its fiscal 2026 guidance for organic net sales growth and adjusted diluted EPS, signaling confidence that the Transform and Modernize initiative is on track. Management highlighted that the sale will reduce exposure to commodity‑driven businesses and strengthen the company’s value‑added protein portfolio.
Analysts noted that the adjusted EPS beat was driven by disciplined cost management and a favorable product mix, while the revenue miss was attributed to weaker demand in the legacy turkey segment and modest pricing pressure in the broader food market. The company’s gross margin remained near 15.7%, reflecting ongoing pressure from commodity costs.
The announcement of the turkey business sale aligns with Hormel’s strategy to focus on higher‑margin, branded products. The transaction is expected to streamline operations and improve profitability, positioning the company for sustainable growth in the long term.
The content on EveryTicker is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.